PMID: 8596317Mar 2, 1996Paper

Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group

Lancet

Abstract

Intravenous heparin is at least as effective as aspirin in preventing new cardiac events after an episode of unstable coronary artery disease (CAD), though the benefits are short-lived. Low-molecular-weight heparin has similar antithrombotic properties but can be given subcutaneously and is therefore suitable for long-term treatment. We have investigated whether subcutaneous low- molecular-weight heparin, in addition to aspirin and antianginal drugs, is protective against new cardiac events in unstable CAD. 1506 patients with unstable CAD (unstable angina or non-Q-wave myocardial infarction) took part in a double-blind trial and were randomly assigned subcutaneous dalteparin (Fragmin; 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days then 7500 IU once daily for the next 35-45 days) or placebo injections. The primary endpoint was the rate of death and new myocardial infarction during the first 6 days. Secondary endpoints were the rates of death and new myocardial infarction after 40 and 150 days, the frequency of revascularisation procedures and need for heparin infusion, and a composite endpoint. During the first 6 days the rate of death and new myocardial infarction was lower in the dalteparin group than in t...Continue Reading

References

Jul 16, 1992·The New England Journal of Medicine·P ThérouxJ McCans
Feb 1, 1989·Scandinavian Journal of Clinical and Laboratory Investigation·E SwahnL Wallentin
Oct 27, 1988·The New England Journal of Medicine·P ThérouxP deGuise
Nov 28, 1985·The New England Journal of Medicine·J A CairnsM G Myers
Mar 1, 1994·Haemostasis·L BadimonJ J Badimon
Jul 1, 1994·American Heart Journal·S KimuraK Shimada
Sep 11, 2004·Mayo Clinic Proceedings·Saaib Al Shehadat, Raymond A Smego

❮ Previous
Next ❯

Citations

Aug 6, 2014·Cardiology Clinics·Sukhdeep S BasraHani Jneid
Sep 14, 2014·Progress in Cardiovascular Diseases·Jorge A Brenes-Salazar, Daniel E Forman
Dec 3, 2014·Revista Portuguesa De Cardiologia : Orgão Oficial Da Sociedade Portuguesa De Cardiologia = Portuguese Journal of Cardiology : an Official Journal of the Portuguese Society of Cardiology·Luísa Lopes-ConceiçãoAna Azevedo
Apr 6, 2001·AACN Clinical Issues·D M Fiorini
Jun 22, 2000·Coronary Artery Disease·Y T ChenH M Krumholz
Nov 6, 1998·British Journal of Clinical Pharmacology·R P Steeds, K S Channer
Jan 23, 1999·BMJ : British Medical Journal·S M Hardman, M R Cowie
Nov 9, 2000·Archives of Medical Research·F López-JiménezG A Lamas
Nov 18, 2000·BMJ : British Medical Journal·A Manhapra, S Borzak
Feb 20, 2003·Heart·M JanzonUNKNOWN Fragmin and Fast Revascularisation during Instability in Coronary Artery Disease II Investigators
Nov 30, 2000·Current Treatment Options in Cardiovascular Medicine·M B Murad, T D Henry
Apr 11, 2003·Current Treatment Options in Cardiovascular Medicine·Richard C. Becker
Jan 17, 2002·Current Treatment Options in Cardiovascular Medicine·John A. Ambrose, Zaheed Tai
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Ganesh Manoharan, A A Jennifer Adgey
May 17, 2007·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Vijay S Ramanath, Kim A Eagle
Sep 29, 1999·Current Opinion in Cardiology·T R Tolleson, R A Harrington
Feb 24, 2001·Current Opinion in Cardiology·C K Wong, H D White
Jun 26, 2004·Current Opinion in Cardiology·Andrew T Yan, Shaun G Goodman
Sep 1, 2005·Der Anaesthesist·J-H SchiffB W Böttiger
Jun 8, 2002·Current Cardiology Reports·Heidar ArjomandMarc Cohen
Sep 12, 2000·Current Cardiology Reports·P J Zed
Sep 12, 2000·Current Cardiology Reports·F A Spencer, R C Becker
Jun 13, 2003·Current Cardiology Reports·Brian NoronhaJonathan A Byrne
Sep 12, 2000·Current Cardiology Reports·C P Cannon
Mar 4, 1998·Australian and New Zealand Journal of Medicine·M DuffyP Rosengarten
May 1, 1997·Clinical Cardiology·C R Conti
Mar 20, 2001·Current Atherosclerosis Reports·D Hunt
Dec 28, 1999·Pharmacotherapy·S A Spinler
May 8, 2007·The Journal of Alternative and Complementary Medicine : Research on Paradigm, Practice, and Policy·Yun Fang LiuYu Xia Zhao
Jul 3, 2007·The Journal of Alternative and Complementary Medicine : Research on Paradigm, Practice, and Policy·Yun Fang LiuYu Xia Zhao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.